Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06294613

A Prospective, Open-label, Single-center, Study of the ACUSURGICAL Luca System for Treatment of Vitreoretinal Diseases

Prospective, interventional, open-label, non-controlled, monocentric study in Belgium of Luca, of up to 15 evaluable subjects, undergoing vitreoretinal surgery to treat intravitreal hemorrhage and macular pucker.

Only one eye per subject can be enrolled.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Given written Informed Consent by subject,
  • Males or females aged 18 - 85 years, pseudophakic or aphakic,
  • Willing and able to comply with the schedule for follow-up visits,
  • Requiring vitrectomy under general anesthesia (conditions include vitreous hemorrhage treatment (with potential clinical conditions including diabetic retinopathy, vascular occlusion, adverse effect of anticoagulant therapy), macular pucker),
  • BCDVA <7/10,
  • Deemed fit for robotic surgery per surgeons' assessment, including ability to undergone general anesthesia,
  • Beneficiary of health insurance.

Exclusion criteria

  • Uncontrolled systemic disease that could increase the operative risk or confound the outcome (autoimmune disease, uncontrolled hypertension, lung and heart disease impairing respiratory function, or any other medical condition as deemed by the Clinical Investigator),
  • BMI (kg/m²) > 30,
  • Axial length <22 or >26 mm per ocular biometry, inclusive,
  • Presence of clinically significant ocular inflammation or infection within 30 days of Preop Visit, such as CME, uveitis, etc.,
  • Ocular condition, that in the opinion of the Clinical Investigator, may predispose for future complications or confound visual acuity results, including profound amblyopia (<1/10) or strabismus,
  • Ocular condition presenting associated pathology likely to require additional surgical manipulation, such as known need for membrane peeling, or retinal neovacular formation to be cut,
  • Already vitrectomized on the study eye,
  • Presenting retinal detachment or retinal tear,
  • History of ocular traumatism; post-traumatic vitreous hemorrhage,
  • Corneal scar preventing clear visualization of fundus,
  • Any associated ocular pathology or ocular degenerative disorder that is uncontrolled such as glaucoma with clinical visual defect or IOP not controlled by medical treatment, uveitis, optic nerve damage,
  • Subjects without light perception,
  • Subject participating in other clinical studies,
  • Subject being dependent on the Sponsor or Clinical Investigator,
  • Pregnant or lactating women, based on self-declaration.

Treatment and study plan

vitreoretinal surgery

Device

Patients undergoing vitreoretinal surgery

Primary outcomes

  1. Safety Outcome

    Time frame: 3 Months

    incidence and severity of investigational device-related (definitely or probably) adverse events, for all subjects treated with the study device (Safety Population).

Study contacts

Contact information is provided by the study sponsor or research team.

Charlene Braun

CONTACT

[email protected]

+33663334352

Sponsors and collaborators

Lead sponsor

Acusurgical

Industry

Registry information

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Mar 5, 2024
Registry last updated
Jan 30, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.